Steven Seedhouse
Stock Analyst at Cantor Fitzgerald
(3.23)
# 1,105
Out of 5,116 analysts
175
Total ratings
47.1%
Success rate
1.92%
Average return
Main Sectors:
Stocks Rated by Steven Seedhouse
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ATXS Astria Therapeutics | Downgrades: Neutral | n/a | $12.95 | - | 3 | Nov 12, 2025 | |
| BCRX BioCryst Pharmaceuticals | Maintains: Overweight | $24 → $26 | $7.63 | +240.76% | 2 | Oct 15, 2025 | |
| DNTH Dianthus Therapeutics | Reiterates: Outperform | $56 → $63 | $41.83 | +50.61% | 4 | Sep 9, 2025 | |
| KRRO Korro Bio | Maintains: Strong Buy | $153 → $147 | $8.12 | +1,710.34% | 3 | Aug 13, 2025 | |
| MIRM Mirum Pharmaceuticals | Maintains: Strong Buy | $77 → $82 | $79.26 | +3.46% | 20 | Aug 7, 2025 | |
| WVE Wave Life Sciences | Initiates: Overweight | $10 | $17.77 | -43.73% | 3 | Apr 29, 2025 | |
| PHVS Pharvaris | Initiates: Overweight | $28 | $25.76 | +8.70% | 1 | Apr 29, 2025 | |
| IFRX InflaRx | Initiates: Overweight | $10 | $1.10 | +809.09% | 14 | Apr 29, 2025 | |
| VKTX Viking Therapeutics | Initiates: Overweight | $104 | $37.18 | +179.72% | 20 | Apr 28, 2025 | |
| QTTB Q32 Bio | Downgrades: Outperform | $90 → $22 | $3.20 | +587.50% | 2 | Dec 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Strong Buy | $6 → $14 | $2.17 | +545.16% | 6 | Oct 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $93 | $124.70 | -25.42% | 9 | Jul 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Strong Buy | $57 → $68 | $53.58 | +26.91% | 3 | May 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Strong Buy | $67 → $106 | $24.97 | +324.51% | 15 | Jan 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Strong Buy | $12 → $15 | $5.74 | +161.32% | 2 | Jan 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Strong Buy | $27 → $56 | $20.04 | +179.44% | 4 | Jan 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $78 → $57 | $9.44 | +503.81% | 10 | Nov 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Strong Buy | $20 → $22 | $4.65 | +373.12% | 2 | Aug 15, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $17 | $2.17 | +683.41% | 6 | Jun 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $33 → $35 | $3.48 | +905.75% | 4 | May 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $38 | $81.32 | -53.27% | 2 | May 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Strong Buy | $30 → $71 | $72.13 | -1.57% | 4 | Dec 15, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $15 → $5 | $3.23 | +54.80% | 5 | Dec 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $30 → $38 | $50.10 | -24.15% | 2 | Nov 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | n/a | $6.16 | - | 7 | Aug 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $10.24 | - | 14 | Aug 5, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $0.87 | - | 5 | May 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $285 → $270 | $12.35 | +2,086.23% | 1 | Aug 6, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sell | n/a | $177.08 | - | 2 | Apr 23, 2020 |
Astria Therapeutics
Nov 12, 2025
Downgrades: Neutral
Price Target: n/a
Current: $12.95
Upside: -
BioCryst Pharmaceuticals
Oct 15, 2025
Maintains: Overweight
Price Target: $24 → $26
Current: $7.63
Upside: +240.76%
Dianthus Therapeutics
Sep 9, 2025
Reiterates: Outperform
Price Target: $56 → $63
Current: $41.83
Upside: +50.61%
Korro Bio
Aug 13, 2025
Maintains: Strong Buy
Price Target: $153 → $147
Current: $8.12
Upside: +1,710.34%
Mirum Pharmaceuticals
Aug 7, 2025
Maintains: Strong Buy
Price Target: $77 → $82
Current: $79.26
Upside: +3.46%
Wave Life Sciences
Apr 29, 2025
Initiates: Overweight
Price Target: $10
Current: $17.77
Upside: -43.73%
Pharvaris
Apr 29, 2025
Initiates: Overweight
Price Target: $28
Current: $25.76
Upside: +8.70%
InflaRx
Apr 29, 2025
Initiates: Overweight
Price Target: $10
Current: $1.10
Upside: +809.09%
Viking Therapeutics
Apr 28, 2025
Initiates: Overweight
Price Target: $104
Current: $37.18
Upside: +179.72%
Q32 Bio
Dec 11, 2024
Downgrades: Outperform
Price Target: $90 → $22
Current: $3.20
Upside: +587.50%
Oct 29, 2024
Upgrades: Strong Buy
Price Target: $6 → $14
Current: $2.17
Upside: +545.16%
Jul 8, 2024
Upgrades: Outperform
Price Target: $93
Current: $124.70
Upside: -25.42%
May 10, 2024
Maintains: Strong Buy
Price Target: $57 → $68
Current: $53.58
Upside: +26.91%
Jan 11, 2024
Maintains: Strong Buy
Price Target: $67 → $106
Current: $24.97
Upside: +324.51%
Jan 9, 2024
Maintains: Strong Buy
Price Target: $12 → $15
Current: $5.74
Upside: +161.32%
Jan 4, 2024
Maintains: Strong Buy
Price Target: $27 → $56
Current: $20.04
Upside: +179.44%
Nov 10, 2023
Maintains: Outperform
Price Target: $78 → $57
Current: $9.44
Upside: +503.81%
Aug 15, 2023
Maintains: Strong Buy
Price Target: $20 → $22
Current: $4.65
Upside: +373.12%
Jun 13, 2023
Upgrades: Outperform
Price Target: $17
Current: $2.17
Upside: +683.41%
May 5, 2023
Maintains: Outperform
Price Target: $33 → $35
Current: $3.48
Upside: +905.75%
May 5, 2023
Upgrades: Outperform
Price Target: $38
Current: $81.32
Upside: -53.27%
Dec 15, 2022
Maintains: Strong Buy
Price Target: $30 → $71
Current: $72.13
Upside: -1.57%
Dec 7, 2022
Maintains: Outperform
Price Target: $15 → $5
Current: $3.23
Upside: +54.80%
Nov 9, 2022
Maintains: Outperform
Price Target: $30 → $38
Current: $50.10
Upside: -24.15%
Aug 10, 2022
Downgrades: Underperform
Price Target: n/a
Current: $6.16
Upside: -
Aug 5, 2022
Downgrades: Market Perform
Price Target: n/a
Current: $10.24
Upside: -
May 18, 2022
Downgrades: Market Perform
Price Target: n/a
Current: $0.87
Upside: -
Aug 6, 2021
Maintains: Outperform
Price Target: $285 → $270
Current: $12.35
Upside: +2,086.23%
Apr 23, 2020
Downgrades: Sell
Price Target: n/a
Current: $177.08
Upside: -